Autologous bone marrow mononuclear cell infusion and hyperbaric oxygen therapy in type 2 diabetes mellitus: an open-label, randomized controlled clinical trial.Related Articles
Autologous bone marrow mononuclear cell infusion and hyperbaric oxygen therapy in type 2 diabetes mellitus: an open-label, randomized controlled clinical trial.
Cytotherapy. 2013 Nov 27;
Authors: Wu Z, Cai J, Chen J, Huang L, Wu W, Luo F, Wu C, Liao L, Tan J
Abstract BACKGROUND AIMS: The use of bone marrow mononuclear cells (BM-MNCs) has achieved great outcomes in clinical practice. We aim to evaluate the efficacy and safety of autologous BM-MNC infusion and hyperbaric oxygen therapy (HOT) in type 2 diabetes mellitus. METHODS: This single-center, randomized, open-label, controlled clinical trial with a factorial design included two phases. The patients received standard medical therapy in the run-in phase; in the treatment phase, patients with glycated hemoglobin of 7.5-9.5% were randomly assigned into four groups and underwent BM-MNC infusion along with HOT (BM-MNC+HOT group), BM-MNC infusion (BM-MNC group), HOT (HOT group) and standard medical therapy (control group), respectively. The area under the curve of C-peptide was recorded as a primary end point. Our research is registered at ClinicalTrials.gov (NCT00767260). RESULTS: A total of 80 patients completed the follow-up. At 12 months after treatment, the area under the curve of C-peptide (ng/mL per 180 min) of the BM-MNC+HOT group and the BM-MNC group were significantly improved (34.0% and 43.8% from the baseline, respectively). The changes were both significant compared with that in the control group, but no remarkable change was observed in the HOT group. Treatment-related adverse events were mild, including transient abdominal pain (n = 5) and punctual hemorrhage (n = 3). CONCLUSIONS: BM-MNC infusion for type 2 diabetes mellitus improves islet function and metabolic control, with mild adverse effects. HOT does not synergize with BM-MNC infusion.
PMID: 24290656 [PubMed - as supplied by publisher]
Interleukin 10 mediates the neuroprotection of hyperbaric oxygen therapy against traumatic brain injury in mice.Related Articles
Interleukin 10 mediates the neuroprotection of hyperbaric oxygen therapy against traumatic brain injury in mice.
Neuroscience. 2013 Nov 26;
Authors: Chen X, Duan XS, Xu LJ, Zhao JJ, She ZF, Chen WW, Zheng ZJ, Jiang GD
Abstract The aim of present study was to elucidate the role of Interleukin-10 (IL-10) in the neuroprotection of hyperbaric oxygen (HBO) against traumatic brain injury (TBI) in mice. The TBI in mice was induced by controlled cortical impact (CCI). HBO was given for 1 hour at 2.0 ATA in 100% O2. HBO enhanced the serumal and cerebral IL-10 protein levels in both sham-operated and TBI mice. HBO therapy after TBI reduced lesion volume, attenuated cerebral edema, improved neurological status including motor and cognitive function, inhibited apoptosis evidenced by decreased ratio of cleaved caspase 3 (C3) to pro-C3 and Bax expression and increased bcl-2 expression, and attenuated inflammation marked by reduced expression of IL-1β, IL-6, macrophage inflammatory protein-2 (MIP-2), and monocyte chemoattractant protein (MCP)-1 and activity of matrix metalloproteinase-9 (MMP9). In addition, HBO after TBI improved blood-brain barrier, and upregulated expression of tight junction proteins including zonula occludens-1 (ZO-1) and claudin-5. IL-10 deficiency aggravated TBI-induced damage in brain and abrogated the beneficial effects of HBO on neuroinflammation, apoptosis, and edema after TBI. IL-10 deficiency itself had no significant effect on brain water content and neurological status. In conclusion, IL-10 played an important role in the neuroprotection of HBO therapy against TBI in mice.
PMID: 24291771 [PubMed - as supplied by publisher]
Other uses for hyperbaric oxygen therapy, such as for radiation-induced necrosis of the brain, are being explored. In recent years, the number of locations offering hyperbaric oxygen therapy in the Cleveland area has grown. Among those with special ...
Idaho State Journal
Jim Jones and Heidi Williams have both been patients in the hyperbaric oxygen chamber at Pocatello's Idaho Doctors Hospital Healing Center and say the treatments have helped their brain injuries and turned their lives around. Posted: Saturday, November
Chambersburg Public Opinion
President and CEO Jason Hawkins said during the past year, FCMC successfully recruited cardiologist Dr. Jeff Mandak, finished the Community Health Needs Assessment, finished the Wound Center complete with the hyperbaric chamber, and installed the
Read the full article here: http://www.publicopiniononline.com/local/ci_24624983/fulton-county-medical-center-reports-strong-financials